Drug-Induced Psychosis vs. Schizophrenia: How Clinicians Tell the Difference
Author: Ukrainian Psychological Hub · Published: October 9, 2026 · Editorial Policy
Drug-induced psychosis and schizophrenia can produce remarkably similar hallucinations, delusions, disorganized thinking, fear, and changes in behavior. Clinicians distinguish them primarily by reconstructing when symptoms began, what substances or medications were involved, whether psychosis occurred before exposure, and what happens during sustained recovery from intoxication or withdrawal. They also investigate mood episodes, delirium, medical illnesses, prior functioning, and the possibility that substance use and an independent psychotic disorder coexist. A single interview, symptom checklist, or positive toxicology test rarely settles the question. NICE clinical guidance recommends a comprehensive history, collateral information when possible, and repeated review of the relationship between substance use and mental state.
The key clinical question is whether a substance plausibly caused the psychosis or whether it triggered, intensified, or happened alongside a primary psychotic disorder such as schizophrenia. Some episodes resolve when exposure ends; others persist or recur. Both presentations deserve prompt treatment and longitudinal follow-up, even when clinicians initially record a provisional diagnosis. This article explains the comparative diagnostic process. For the broader condition, see Substance-Induced Psychosis: Causes, Symptoms, and Treatment and Schizophrenia: Symptoms, Causes, Diagnosis, Treatment, and Recovery.
The Difference in One Clinical Comparison
Substance/medication-induced psychotic disorder is diagnosed when prominent psychotic symptoms emerge in a credible temporal and causal relationship with exposure to a substance, medication, intoxication, or withdrawal, and another disorder provides no better explanation. Schizophrenia is a primary psychotic disorder defined by a qualifying constellation of symptoms, changes in functioning, and duration, with substance, medication, mood, and medical causes assessed before the diagnosis is confirmed. The SAMHSA guidance summarizing DSM-5 substance-induced criteria and NIMH schizophrenia overview describe the relevant distinctions.
In a presentation more consistent with substance-induced psychosis, symptoms follow a plausible drug exposure or withdrawal and may diminish as the acute effects recede. In a presentation more consistent with schizophrenia, psychosis may predate exposure, continue independently of substance effects, or recur during verified periods without relevant exposure; a longer pattern of functional deterioration, negative symptoms, or disorganization may also contribute. These features shift probability rather than functioning as definitive tests. The actual diagnosis integrates the full clinical course.
What Counts as Psychosis—and What Does Not Establish Schizophrenia?
Psychosis describes impaired reality testing associated with experiences such as hallucinations, delusions, and disorganized thought or behavior. A hallucination is a perception-like experience without a corresponding external stimulus; a delusion is a firmly held belief that remains resistant to adequate contradictory evidence and is assessed within cultural and clinical context. Disorganized speech can reflect disturbed thought processes. None of these findings, alone, identifies the cause. The National Institute of Mental Health explains that psychosis has multiple potential psychiatric, substance-related, and medical causes.
Schizophrenia requires formal clinical criteria, including characteristic symptoms, meaningful disturbance of functioning, and an overall duration pattern that reaches at least six months under DSM-5-TR, with an active phase typically lasting at least one month unless successfully treated. Different conditions can account for shorter or differently patterned episodes. A diagnosis of schizophrenia is never inferred merely because a person heard a voice, was suspicious after cannabis use, or had a severe emergency presentation. Read How Is Schizophrenia Diagnosed? for the complete diagnostic framework.
How Clinicians Separate the Two Diagnoses
1. Reconstruct the timeline before interpreting the symptoms
Clinicians draw an explicit chronology: baseline functioning; earliest changes in sleep, social engagement, work, studies, mood, or unusual beliefs; first intoxication or withdrawal; escalation in dose or potency; onset of hallucinations or delusions; emergency visits; treatment; and changes after substance use stops. They distinguish a psychotic episode that clearly preceded exposure from one starting during a plausible period of intoxication or withdrawal. Family members, friends, previous clinicians, pharmacy records, and earlier records may help corroborate dates when memory is affected by illness or intoxication.
A person can have used cannabis for years before a first episode; that history alone does not establish that cannabis caused the episode. Conversely, abrupt onset after heavy stimulant exposure makes a substance-related contribution clinically important without excluding a coexisting vulnerability. Dose, route, frequency, combinations, changes in formulation, medication starts and stops, and exposure to unfamiliar products all matter. The NICE assessment recommendations specifically call for documenting the particular substances, amounts, frequency, routes, and duration of use.
2. Identify whether the exposure could plausibly cause psychosis
A credible exposure must have a known potential to produce the observed syndrome. Clinicians consider high-potency cannabis products, amphetamines and methamphetamine, cocaine, some hallucinogens, and particular prescription or over-the-counter medications. Certain withdrawal states, especially involving alcohol or sedative-hypnotics, require simultaneous assessment for delirium, seizures, autonomic instability, and other medical complications. Poly-substance exposure can obscure the picture because sedatives, stimulants, alcohol, sleep deprivation, and other agents may act together.
Exposure history is interpreted within a differential diagnosis: substance use can precipitate a transient syndrome, amplify an existing schizophrenia-spectrum disorder, or coexist without being the main cause. A medication association also requires scrutiny of dosing, indication, interactions, and the underlying illness. The label 'drug-induced' should describe a supported etiologic judgment, not serve as shorthand for 'this person uses drugs.'
3. Observe what happens after acute exposure and withdrawal end
Symptom reduction over an appropriate period without the suspected trigger increases support for a substance-induced explanation. Continuing psychosis during a credible interval of abstinence, especially with other characteristic features, raises concern about an independent psychotic disorder. However, clinical timelines differ across substances and individual cases, and improvement may reflect antipsychotic treatment, sleep recovery, reduced stress, medical stabilization, or several factors simultaneously.
DSM-based teaching materials describe persistence for a substantial interval—illustratively around one month after acute intoxication or withdrawal—as a reason to consider an independent disorder. This is a diagnostic clue, not a universal waiting period or an automatic schizophrenia rule. Some substance-associated psychoses persist for weeks or longer, some primary psychoses improve rapidly, and a person may be unable to establish a reliable abstinence history. SAMHSA TIP 42 outlines the independent-disorder clues; the 2026 systematic review by Ricci and colleagues underscores the considerable overlap and limited stability of diagnoses made from a single encounter.
4. Look for an independent course before and between exposures
Previous psychotic episodes unrelated to substance use, earlier psychiatric documentation, or a recurrence after an extended period without the suspected trigger increases the likelihood of an independent disorder. Clinicians also ask whether there were months of deterioration in school, work, self-care, communication, or relationships before the identifiable drug exposure. A long-standing functional change matters, yet depression, trauma, poverty, neurodevelopmental conditions, sleep disorders, and substance use itself can produce similar problems; clinicians must establish the cause of each apparent change.
5. Evaluate symptom dimensions without treating them as fingerprints
Persecutory delusions, auditory hallucinations, visual hallucinations, thought disorder, agitation, and unusual sensory experiences can occur in both conditions. Some studies describe more affective symptoms or relatively preserved negative-symptom domains in certain substance-induced groups, but the distributions overlap markedly. Persistent negative symptoms—such as diminished motivation or emotional expression—and impaired premorbid functioning can increase concern about a longer-lasting disorder. They are not proof of schizophrenia, especially when depression, medication effects, withdrawal, or social disruption could explain them.
A 2026 systematic review examining 36 studies and more than 80,000 participants found substance-specific phenomenological patterns but also substantial overlap and diagnostic instability. Another 2026 systematic review of prognosis and treatment response reported associations involving onset pattern, negative symptoms, and prior functioning; the strength and generalizability of prognostic evidence vary. Clinicians therefore use these features as part of a broader formulation and avoid diagnosing from the 'type of voice' or the content of delusions.
6. Rule out medical and mood-related explanations
An apparent drug-related psychosis may coincide with hypoglycemia, infection, metabolic disturbances, seizures, head injury, neurologic illness, toxic exposure, medication toxicity, or delirium. Acute confusion, fluctuating attention, disorientation, autonomic instability, fever, seizures, or a changing level of consciousness raises special concern for medical causes. Delirium must be distinguished from psychosis occurring with relatively preserved attention and alertness. Clinicians also evaluate psychotic episodes in bipolar disorder and major depressive disorder, where the relationship to substantial mood episodes is diagnostically decisive.
A family should not infer schizophrenia from an emergency department note that says 'psychosis, unspecified.' Such provisional documentation often expresses uncertainty while assessment continues. See Psychosis Due to a Medical Condition for medical differential diagnosis and Schizophrenia vs. Bipolar Disorder for the separate mood-psychosis comparison.
Why a Drug Test Cannot Diagnose the Cause
Urine or blood toxicology can assist with the exposure history when the result is clinically relevant, consent and policy requirements are met, and the limitations are understood. A positive result can reflect prior exposure rather than intoxication at the moment psychosis began. A negative result cannot exclude every drug, synthetic compound, medication, exposure outside the detection window, or false-negative assay result. Screening immunoassays may cross-react, and confirmation sometimes requires a different laboratory method. No toxicology result independently tells a clinician whether schizophrenia is present.
A person's report of abstinence is also a clinical datum rather than a moral test of credibility. A careful assessment combines laboratory information, medication records, symptom course, physical findings, and collateral history with respect for privacy. NICE CG120 advises that biological testing may be helpful in an agreed care plan but should not be used as routine substance-misuse screening in people presenting with psychosis.
How Long Can Drug-Induced Psychosis Last?
Duration depends on the substance, potency, amount, repeated exposure, comorbid illness, sleep deprivation, physiologic withdrawal, treatment, and individual susceptibility. Symptoms sometimes improve over hours or days; others continue for weeks, and persistent or recurrent syndromes require renewed diagnostic assessment. A person cannot use a fixed '24 hours,' 'seven days,' or '30 days' cut-off to decide whether the diagnosis is schizophrenia.
The practical interpretation of roughly a month is that sustained psychosis after an adequate interval beyond acute intoxication and withdrawal makes a primary disorder more important to investigate. It is not a rule that all cases resolving within a month are drug-induced or that all cases lasting longer are schizophrenia. Accurate differentiation may require repeated appointments over months, particularly after a first episode or when abstinence is difficult to document. The SAMHSA DSM-5 diagnostic summary provides the general temporal reasoning, while NICE recommends ongoing review as substance use and mental state change.
Cannabis-Induced Psychosis vs. Schizophrenia
Cannabis can be temporally associated with psychotic symptoms, and cannabis-induced psychosis is a clinically recognized category when full diagnostic conditions are met. High-potency products, repeated exposure, mixed drug use, and the person's underlying vulnerability influence clinical assessment. During an acute episode, hallucinations, persecutory beliefs, and intense anxiety may resemble the presentation of schizophrenia. The diagnostic task remains historical and longitudinal: onset relative to cannabis exposure, preceding psychotic symptoms, independent recurrence, course of functioning, and sustained abstinence.
Cannabis-related presentations are especially important to follow. In a 2020 meta-analysis, the pooled proportion receiving a later schizophrenia diagnosis after cannabis-induced psychosis was 34% across the included studies, though estimates varied. In a 2023 Norwegian registry study, cannabis-associated episodes were among the highest-risk categories for later schizophrenia-spectrum diagnosis. These are population-level associations among people already diagnosed with psychosis; they are not individual predictions and do not establish that every subsequent schizophrenia diagnosis was biologically caused by cannabis.
Methamphetamine, Amphetamines, and Cocaine
Stimulant-associated psychosis can involve intense suspiciousness, auditory or visual hallucinations, unusual tactile sensations, sleep loss, agitation, and disorganized behavior. Symptoms may begin amid heavy or repeated use, sleep deprivation, or changing doses. A history of stimulant exposure is relevant, but the same symptom pattern can coexist with schizophrenia or another disorder. Clinicians ask about repeated episodes, abstinence periods, preceding impairments, and whether symptoms persist after acute stimulant effects have subsided.
The Murrie and colleagues meta-analysis estimated subsequent schizophrenia diagnoses in 22% of the amphetamine-induced group across five included studies; the precision and applicability of any subgroup estimate depend on the cohort and follow-up. The 2026 phenomenology review notes that methamphetamine-related symptoms can range from transient episodes to persistent presentations. Severe agitation, overheating, cardiac complaints, seizures, or inability to care for oneself require urgent medical evaluation independent of the eventual psychiatric diagnosis.
Alcohol, Hallucinogens, Prescription Medications, and Mixed Exposures
Alcohol-related psychotic symptoms require assessment of whether they arose during intoxication, withdrawal, another alcohol-related syndrome, or an independent disorder. Severe alcohol withdrawal may include delirium tremens, a medical emergency with confusion and autonomic disturbance. Withdrawal from certain sedatives carries similar dangers. Hallucinogen-associated perceptual disturbances also need differentiation from delirium, a psychotic disorder, and hallucinogen persisting perception disorder. These categories cannot be collapsed into one timeline.
Prescription medications, including some stimulants and corticosteroids, may be relevant when symptoms begin after initiation, dose changes, interactions, or withdrawal. Clinicians review all prescribed medications, supplements, and nonprescribed substances rather than assuming an illicit drug is responsible. Medication-associated symptoms should be assessed by a qualified prescriber; abruptly discontinuing an essential medication or attempting unsupervised alcohol or sedative withdrawal can create additional risk.
What About Family History, Negative Symptoms, and Premorbid Functioning?
Family history of schizophrenia-spectrum or other psychotic disorders may increase suspicion of a vulnerability to primary psychosis. Its absence does not exclude schizophrenia, and its presence does not prove that a particular episode is independent of substances. Similarly, persistent negative symptoms, cognitive difficulties, or a prolonged decline in self-care can inform the differential, but clinicians must assess depression, residual intoxication, medication adverse effects, environmental deprivation, and other conditions before attributing them to a primary psychotic disorder.
A 2026 review of predictors identifies premorbid functioning and negative-symptom burden as potential prognostic factors in substance-induced psychosis, with varying certainty across factors. The safest way to apply this research is to plan proportionate follow-up and rehabilitation, rather than use individual characteristics as a deterministic prognosis.
Can Drug-Induced Psychosis Turn Into Schizophrenia?
A later diagnosis of schizophrenia after an initial substance-induced psychosis is a documented clinical outcome. The term 'transition' in longitudinal research describes a change in recorded diagnosis over time; it does not, by itself, establish a single causal pathway. Some people may have experienced an early manifestation of primary psychosis that was initially difficult to recognize because substance use was present. In other cases, exposure may have contributed to onset in a vulnerable person. The available registry and meta-analytic designs cannot reliably distinguish these explanations for every individual.
The 2020 systematic review and meta-analysis by Murrie and colleagues pooled 25 studies of substance-induced psychosis involving 34,244 participants and estimated a later schizophrenia diagnosis in 25% overall (95% confidence interval 18%–35%). Estimates differed across substances, study populations, diagnostic approaches, and follow-up. This figure is not the probability that a random person who uses drugs will develop schizophrenia: the study population consisted of people who had already experienced substance-induced psychosis.
A separate 2023 Norwegian registry cohort of 3,187 patients found a six-year cumulative transition estimate of 27.6% to a schizophrenia-spectrum disorder and 4.5% to bipolar disorder. Younger men, cannabis or multiple-substance presentations, and repeated emergency admissions were associated with higher subsequent schizophrenia-spectrum diagnosis rates in particular analyses. The studies reinforce the need for ongoing specialist follow-up while leaving individual outcomes open.
Sustained recovery from the acute episode is possible, and an initial label may be revised as clinicians obtain better evidence. Persistent symptoms should prompt further treatment and diagnostic reconsideration; they do not justify declaring a lifelong prognosis at the first visit. WHO and NIMH emphasize that effective care and support can improve functioning and quality of life in people with schizophrenia.
What Happens During a Real Clinical Assessment?
Immediate safety and medical stabilization
The first task is to assess vital signs, hydration, consciousness, temperature, agitation, self-harm risk, inability to care for basic needs, medication toxicity, withdrawal complications, and urgent neurologic or medical symptoms. Clinicians may involve emergency medicine, psychiatry, toxicology, or other specialists. A person who is severely confused, febrile, having seizures, experiencing chest pain, unusually rigid or unresponsive, or expressing an imminent intention to harm themselves needs emergency assessment. Treatment begins before the long-term diagnostic label is fully resolved.
Structured psychiatric and substance-use history
The clinician documents psychotic symptoms, insight and distress, mood and sleep changes, trauma history, lifetime substance exposure, medication history, earlier episodes, family history, and changes in social or occupational functioning. Existing psychiatric diagnoses are reviewed rather than treated as irrevocable. Collateral history, with appropriate consent, helps establish a meaningful timeline and avoid both missing psychosis and attributing every symptom to substance use. NICE CG120 calls for comprehensive multidisciplinary assessment and periodic review.
Physical examination and targeted investigations
Tests are selected for the clinical presentation. Depending on circumstances, these can include basic laboratory studies, pregnancy testing when appropriate, ECG, toxicology, infectious or metabolic assessment, and selective neurologic evaluation. Brain imaging or specialized investigations depend on examination findings and red flags rather than functioning as a routine 'schizophrenia test.' NICE CG178 outlines assessment of physical health and medical context in first-episode psychosis.
Working formulation and follow-up
The clinician may initially document 'first-episode psychosis,' 'unspecified psychosis,' or a provisional substance-induced disorder. Reassessment then examines symptom persistence, medication response, relapse, functional recovery, repeated use, and a credible exposure-free interval. The working diagnosis can evolve as additional history and observation become available. First-Episode Psychosis: Early Signs, Assessment, Treatment, and Recovery explains the broader early-care pathway.
Three Clinical Examples That Show Why Timing Matters
Example A: Symptoms begin after a new exposure
A person with no documented earlier psychotic episodes develops persecutory beliefs and hears voices after several nights of intensive stimulant use and little sleep. The symptoms ease with medical stabilization, sleep recovery, and treatment. This timeline supports a substance-induced formulation, but the clinician still investigates prior functioning, other causes, and relapse risk, and arranges follow-up. Improvement alone does not retrospectively prove a single cause.
Example B: Psychosis predates the drug use
A student has several months of progressive thought disorganization, reduced functioning, and emerging delusional beliefs before beginning cannabis use. Psychosis subsequently worsens during heavy use. Substance use may have aggravated symptoms, yet the predating syndrome increases concern about a primary psychotic disorder. Diagnosis then depends on the full schizophrenia-spectrum, mood, medical, and duration criteria rather than simply the cannabis history.
Example C: Symptoms persist despite reported abstinence
A patient has a severe psychotic episode linked in time to a drug exposure, but voices and delusions continue beyond acute withdrawal while follow-up records suggest no further exposure. Clinicians reconsider the initial explanation and assess for primary psychosis, residual substance effects, medication and medical causes, and the reliability of the timeline. A persistence interval strengthens the need for review; it is not a substitute for evaluating schizophrenia criteria.
These are educational composites, not real patient histories, and none of them provides a diagnosis for a reader whose experience resembles the example.
Treatment While the Diagnosis Is Still Uncertain
Clinical urgency is determined by symptom severity, medical stability, safety, and functional impairment. Treatment can include a calm, low-stimulation environment, medical management of intoxication or withdrawal, sleep restoration, short-term medication when clinically indicated, and specialist psychiatric care. Antipsychotic medication may be used for significant psychotic symptoms, but drug choice, dose, monitoring, interactions, and treatment duration depend on the individual case. No reader should initiate, abruptly discontinue, or change antipsychotics based on this comparison.
For psychosis coexisting with substance misuse, NICE CG120 advises evidence-based treatment of both conditions and states that evidence does not establish a preferential antipsychotic solely for this combined presentation. The guideline recommends attention to substance–medication interactions and collaborative care. Where schizophrenia is confirmed, ongoing antipsychotic treatment, psychosocial support, and relapse planning may be indicated under established clinical guidance, including the APA schizophrenia practice guideline and NICE CG178.
Cognitive behavioral therapy for psychosis, family psychoeducation, help with education or employment, case management, and coordinated specialty care can be relevant depending on diagnosis and needs. An individual with both psychosis and problematic substance use should have accessible psychiatric care and appropriate substance-use services rather than being rejected by either system. NICE CG120 explicitly addresses this barrier. The English Hub discusses condition-specific approaches in Schizophrenia Treatment and Coordinated Specialty Care for First-Episode Psychosis.
Why Follow-Up Matters Even After Symptoms Stop
When voices or delusions disappear, clinicians still consider recurrence, emerging mood episodes, lingering cognitive or functional problems, physical health, sleep, housing, work, relationships, and the possibility of renewed substance exposure. A follow-up plan typically clarifies who to contact if symptoms return, which warning signs require reassessment, how treatment will be reviewed, and where substance-use support is available. The appropriate duration of monitoring reflects clinical history and risk, not a universal calendar.
Individuals and families benefit from clear documentation of the initial diagnostic uncertainty. A statement such as 'psychosis probably associated with recent stimulant exposure; primary psychotic disorder remains under review' can be more accurate at an early encounter than a definitive label. Shared decision-making should explain what the clinician knows, what remains unresolved, and what new information could change the formulation.
When to Seek Urgent Help
New hallucinations or fixed delusional beliefs merit prompt medical or mental-health assessment, especially after substance exposure or withdrawal. Emergency services are appropriate when a person is suicidal or unable to stay safe, becomes severely disoriented, has seizures, high fever, severe agitation, marked muscle rigidity, loss of consciousness, chest pain, or signs of dangerous withdrawal. Sudden confusion is particularly important because delirium and toxic or metabolic emergencies need immediate medical care. In the United States, 911 is appropriate for a medical emergency and 988 provides suicide and mental-health crisis support; elsewhere use local emergency and crisis services.
A helpful response from relatives is to speak calmly, avoid arguing about the factual content of unusual beliefs, ask about immediate safety and medical symptoms, and assist the person in accessing care. Substance-related stigma and fear of punishment can deter truthful disclosure, so respectful questions and confidentiality matter. See How to Help Someone Experiencing Psychosis for family communication and safety principles.
Frequently Asked Questions
Can doctors tell the difference during the first hospital visit?
Sometimes the history and medical findings strongly support one explanation. Frequently, an initial visit establishes a working diagnosis, with further assessment needed after stabilization and follow-up. Reliable timing and previous episodes may be unavailable during acute illness.
If psychosis stops after quitting drugs, does that rule out schizophrenia?
No. Improvement after substance cessation supports a possible substance-related explanation, but treatment, recovery from sleep deprivation, stress reduction, and an episodic primary disorder can also influence symptoms. Longitudinal history remains essential.
If psychosis lasts more than a month, is it definitely schizophrenia?
No. Persistence beyond acute intoxication or withdrawal increases concern for an independent disorder and calls for careful reassessment. Schizophrenia additionally requires its own symptom, duration, functional, and exclusion criteria. Persistent substance-associated syndromes and other psychiatric or medical diagnoses remain possible.
Can schizophrenia and a substance-use disorder occur together?
Yes. A person can meet criteria for both. Substance exposure may worsen psychosis or complicate treatment without fully explaining the underlying disorder. Care should address both needs in a coordinated, nonjudgmental plan.
Can a urine drug screen prove that drugs caused hallucinations?
No. It can contribute exposure information within test-specific detection limits. It cannot directly establish causation, the timing of psychosis, or the absence of primary schizophrenia.
Does the kind of hallucination show which diagnosis is correct?
No. Although some sensory experiences are reported more often with certain substances, the distributions overlap. The timeline, full mental-state assessment, medical findings, functioning, and follow-up are more informative than the voice or vision alone.
How likely is a later schizophrenia diagnosis after substance-induced psychosis?
Research estimates vary. A 2020 meta-analysis reported a pooled 25% transition estimate for schizophrenia across included cohorts, whereas a 2023 Norwegian registry study estimated 27.6% to schizophrenia-spectrum diagnoses over six years. Neither number provides a personalized prognosis.
Should a person stop prescribed medication if they suspect it caused psychosis?
A suspected medication adverse effect warrants urgent discussion with the prescribing clinician or emergency assessment according to severity. Unsupervised discontinuation may itself be dangerous, especially with medications that require tapering or when withdrawal can cause complications.
What is the most useful information to bring to an appointment?
A dated symptom timeline; medication names and recent changes; substances used, approximate doses and times; sleep history; earlier episodes; medical problems; and observations from a trusted person can all help. If details are uncertain, saying so is clinically useful.
Clinical Takeaway
Drug-induced psychosis versus schizophrenia is a longitudinal differential diagnosis. Clinicians combine a credible exposure history, a detailed symptom timeline, pre-exposure functioning, examination and targeted investigations, symptom course during recovery, and evidence of independent episodes. Acute safety comes first, a provisional diagnosis is often appropriate, and ongoing care can improve outcomes regardless of which formulation ultimately proves most accurate.
Related Articles
References
American Psychiatric Association. (2020). The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Official guideline.
Murrie, B., Lappin, J., Large, M., & Sara, G. (2020). Transition of substance-induced, brief, and atypical psychoses to schizophrenia: A systematic review and meta-analysis. Schizophrenia Bulletin, 46(3), 505–516. https://doi.org/10.1093/schbul/sbz102.
National Institute for Health and Care Excellence. (2011; updated 2024). Coexisting severe mental illness (psychosis) and substance misuse: Assessment and management in healthcare settings (CG120). NICE guidance.
National Institute for Health and Care Excellence. (2014). Psychosis and schizophrenia in adults: Prevention and management (CG178). NICE guidance.
National Institute of Mental Health. (n.d.). Schizophrenia. NIMH.
National Institute of Mental Health. (n.d.). Understanding psychosis. NIMH.
Ricci, V., Chiappini, S., Martinotti, G., & Maina, G. (2026). From substance-induced psychosis to schizophrenia: Predictors of treatment response and transition to chronic psychotic illness—A systematic review. Schizophrenia Research, 295, 292–316. https://doi.org/10.1016/j.schres.2026.02.022.
Ricci, V., Martinotti, G., & Maina, G. (2026). A systematic review of clinical phenomenology, differential diagnosis and prognostic outcomes of substance-induced psychotic disorders. International Journal of Social Psychiatry, 72(5), 1070–1086. https://doi.org/10.1177/00207640261439774.
Rognli, E. B., Heiberg, I. H., Jacobsen, B. K., Høye, A., & Bramness, J. G. (2023). Transition from substance-induced psychosis to schizophrenia spectrum disorder or bipolar disorder. American Journal of Psychiatry, 180(6), 437–444. https://doi.org/10.1176/appi.ajp.22010076.
Substance Abuse and Mental Health Services Administration. (2020). Substance use disorder treatment for people with co-occurring disorders (Treatment Improvement Protocol 42). NCBI Bookshelf.
World Health Organization. (n.d.). Schizophrenia. WHO fact sheet.